Tivozanib Hydrochloride is the hydrochloride salt of tivozanib. It is an oral VEGF receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Fotivda is one of the many brand names that are used to refer to tivozanib hydrochloride.
Tivozanib was granted permission for use in the treatment of medical conditions in the European Union in August 2017, and in the United States in March 2021.
|Name of Product||Tivozanib hydrochloride|
|Synonyms||Cloridrato de Tivozanibe; Clorhidrato de tivozanib; Tivozanib hydrochloride; Chlorhydrate de tivozanib|
|Molecular Weight||509.3 g/mol|
|2||Appearance (Colour)||White to beige|
|3||Solubility||DMSO: 2 mg/mL, clear|
The drug tivozanib belongs to a group of medicines known as kinase inhibitors. It works by blocking the action of vascular endothelial growth factor (VEGF), the abnormal protein that signals cancer cells to multiply, thus suppresses angiogenesis. This assists in preventing or slowing the spread of cancer cells. Its purpose is to block the activity of all three VEGF receptors.
Tivozanib is prescribed to people who have undergone two or more previous systemic treatments for their advanced renal cell carcinoma (RCC, cancer that begins in the kidneys) and have experienced a relapse or a lack of response to those treatments.
Common side effects associated with the use of Tivozanib hydrochloride include:
Some of the serious side effects include:
Q. Is it safe to consume Tivozanib during pregnancy?
Tivozanib should not be taken during pregnancy because it could potentially cause teratogenic effects.
Q. Is Tivozanib FDA approved?
Tivozanib, a kinase inhibitor, was granted approval by the Food and Drug Administration (FDA) on March 10, 2021 for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC) in adult patients who had previously undergone two or more systemic treatments.